Surveillance and Tracking the Outcomes of Chronic Latent EBV Infection
ConditionEBV Infection
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorHuazhong University of Science and Technology
About this trial
Immunocompetent subjects with high load of Epstein-Barr virus DNA (EBV-DNA) in peripheral blood will be enrolled and prospectively followed up to track the natural histories of the chronic high load of EBV virus. The primary goal of this study is to explore the association of peripheral high load of EBV with the hematological malignancies, and second goal is to investigate the genetic mechanisms of immune escape and tumorigenesis of chronic EBV infection.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
immunocompetent subjects who was found to have high EBV-DNA load （>1×103 copies/ml）in peripheral blood during the physical examination
Willing to be followed up by telephone or face-to-face interview
Disqualifiers
Subjects with defined immunodeficiency
Subjects who have taken or are going to take immunosuppressive drugs.
Subjects Diagnosed a validated hematopathy
Subjects diagnosis as precancerous lesion or malignant tumor and the life expectancy is less than 1 year.
Trial population
A cohort of immunocompetent subjects with high load (\>1×103 copies/ml) of Epstein-Barr virus DNA (EBV-DNA) in peripheral blood will be enrolled and prospectively followed up to track the natural histories of the chronic latent EBV infection.The subjects were enrolled from healthy examers in Tongji Hospitoal attached to Huazhong University of Science and Techonology. There is no limitation regarding to age and sex.
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
peripheral EBV-DNA load
Other interventionNo intervention
Treatment groups
10,000 Participants
are divided into 1 treatment groupGroup A: peripheral EBV-DNA load1 intervention
Trial outcomes
Primary outcomes
1
hematological malignancies
including Burkitt lymphoma, EBV+ B-cell lymphoproliferative diseases, extranodal NK/T-cell lymphoma of nasal type (ENKL), aggressive NK-cell leukemia (ANKL), classic Hodgkin lymphoma, and Chronic active Epstein-Barr virus infection (CAEBV).
Time frame
Five years or more if necessarySponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov